Foremed Legend Co-Hosts the 2023 Future Healthcare 100 Summit – Forum on Innovation and Development in Photonic Aesthetics

Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global upheavals and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic deployments outlined at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “stand firm amidst countless trials and tribulations,” and embodying the spirit to “press forward despite increasing difficulties,” can innovators in the healthcare sector reinforce their confidence through decisive action, thereby delivering a commendable response to the era’s call for high-quality development in healthcare.

The 7th Future Healthcare 100 Conference, themed “No Boundaries,” was organized by VCBeat and Eggshell Institute, in strategic partnership with Shanghai Zhangjiang Group. Integrating cutting-edge academic research insights, comprehensive industry perspectives, and keen capital market trends, the event took place from May 5–7, 2023, at the Zhangjiang Science Hall in Shanghai. Together with industry peers, it explored the innovative future of the broader health sector, embarking on a new journey in healthcare innovation.

After six editions, the conference has become China’s largest and most information-rich ecosystem summit for the integration of industry and capital in the healthcare innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the future of technology, and focusing on venture capital interaction,” it sets the direction for innovation and investment in China’s healthcare field. The 7th Future Healthcare Top 100 Conference in 2023 will feature three major summits, more than 20 thematic forums covering specialized areas, the release of the Future Healthcare Top 100 series rankings and awards, over ten series reports, and seven concurrent networking events. Distinguished guests and attendees—including government agencies, academicians and scientists, clinical and research experts, Fortune 500 and listed companies, top-tier investment institutions and securities firms, and innovative healthcare enterprises—will gather for this meeting of minds to provide insights for the industry and usher in a new future.

“Ask only of courage, ask only of blooming; ask not of west or east” arrives with full force!

According to Frost & Sullivan data, despite the impact of the pandemic, market growth for non-surgical procedures remained remarkably strong. In 2020, the market size for non-surgical procedures in China increased by 28.8% year-over-year, while the market size for surgical procedures decreased by 7.2% during the same period. In 2021, the global market growth rates for surgical and non-surgical procedures were 10.3% and 23%, respectively; in China, the corresponding growth rates were 17.9% and 26.4%, respectively.

From the perspective of market share, China’s non-surgical medical aesthetics market accounted for 52% of the total market size in 2021. In the future, driven by the expanding product categories and iterative upgrades of minimally invasive aesthetic treatments, China’s non-surgical market is expected to further expand, with its share projected to reach 65% by 2030.

Amid the mainstreaming of “light medical aesthetics,” the energy-based device sector in medical aesthetics has witnessed explosive growth. According to the latest data released by So-Young, 47.34% of surveyed users identified energy-based procedures as their most favored or most desired medical aesthetic treatments in China in 2022.

Due to high technical barriers, China’s market for photoelectric medical aesthetic devices has long been monopolized by imported foreign equipment. In the mid-to-high-end segment, imports account for more than 80% of the market share, leaving substantial room for domestic brands to capture market share through substitution. Meanwhile, as market awareness grows and regulatory frameworks become more standardized, China’s photoelectric medical aesthetic device market is gradually maturing. Amid the trend of domestic substitution in this field, a cohort of high-quality innovative enterprises is emerging in China, signaling that the golden window of opportunity in this sector has arrived!

In this context, byVB100 by VCBeat and Fumilei Jointly Host the Forum on Innovative Development of Photoelectric Medical Aesthetics and Release the "White Paper on Energy-Based Devices in Medical Aesthetics"The event will be held at the 7th Future Healthcare Top 100 Conference. The forum will bring together core resources for industrial innovation, focusing on the hot sector of high-end medical devices—photoelectric aesthetic medicine equipment. By gathering top industry experts and leaders, leveraging their keen insights into the industry and continuous innovative practices, the forum aims to build a communication platform for the aesthetic medicine industry and create a premier industrial exchange showcase.

Suzhou Fumailai Medical Technology Co., Ltd., established in September 2021, with its core founding team hailing from renowned universities both in China and abroad, such as Peking University. The company is committed to becoming a leading global manufacturer of high-end medical aesthetic optoelectronic devices. As an R&D-driven technology enterprise, Fullmire currently has R&D personnel accounting for over 60% of its workforce, with more than 50% holding master’s degrees or higher. It has successfully obtained two invention patents (of global first-of-their-kind level), three utility model patents, and two design patents. In 2022, it consecutively completedAngel RoundandPre-Series A Financing, which is highly favored by the capital market. The current product pipeline under development includes picosecond lasers, long-pulse lasers, and non-ablative fractional lasers, with full product line coverage of mainstream laser and IPL treatment devices to be achieved within two years.

In March 2023, Fulmilei’s patent application titled “Photoacoustic Tomography and Ultrasound Imaging System and Method Based on Multiple Ultrasonic Transducers” successfully passed the rigorous examination by the China National Intellectual Property Administration (CNIPA) and was granted an invention patent. Two weeks later, Fulmilei’s another patent application titled “Multi-Wavelength Picosecond Laser Cosmetic Device Guided by Photoacoustic Imaging and Its Control Method” was also granted an invention patent. These two patents demonstrate strong innovativeness and hold significant importance for the integration of diagnosis and treatment in dermatological laser therapy.

Fumilai firmly believes that with technological advancements, scientific and visualized quantitative skin diagnosis is an inevitable trend. Progress in diagnostic technologies will drive the integrated development of diagnosis and treatment in dermatology, bringing about completely disruptive opportunities for industry growth. Based on this,Mr. Xia Yuqing, Founder of FumailaiHe/She will attend the forum and deliver a keynote speech, sharing insights and explorations on Fumailai’s integrated approach to dermatological diagnosis and treatment. We look forward to engaging with industry professionals in exploring the opportunities and challenges shaping the sector’s development, sparking intellectual exchange, and fostering ecosystem collaboration.

At this forum, we are honored to have invited Professor Li Changhui, Deputy Head of the Department of Biomedical Engineering at Peking University and a leading international expert in photoacoustic imaging, to share insights on the cutting-edge developments in photoacoustic imaging technology. Technological innovations in lasers also bring new opportunities for laser therapy; accordingly, the forum has also invited Professor Zhang Huanian from Shandong University of Technology to discuss frontier technological innovations in the field of lasers.

Furthermore, we have invited Dr. Liu Fei, founder of Minovate, to share cutting-edge explorations into the combined use of medical aesthetic energy-based devices and pharmacological therapies, offering a novel perspective on the developmental trajectory of energy-based aesthetics. The rise of domestic brands has been accompanied by an arduous journey of brand building, a challenge equally pertinent to domestic medical aesthetic energy-based device manufacturers. To address this, we have specially invited Mr. Zhou Shuyang, founder of Yimu Vision, to discuss how the world’s most advanced medical visualization technologies contribute unique value to the brand development of domestically produced medical aesthetic energy-based devices.

During the roundtable discussion, we have invited Ms. Zhou Xinling, Investment Director at Warburg Pincus, and Mr. Chen Long, Managing Director at Zhouling Capital. We are confident that these two seasoned investors will provide highly constructive guidance on the development trajectory of domestically produced optoelectronic equipment. With the rise of domestic brands and compliance as a top priority, we have also invited Mr. Ma Chenglong, Partner at ZhiDe Law Firm, to delve into practical recommendations regarding regulatory compliance and intellectual property protection.

Conference Time:

May 5–7, 2023

Time of the Forum on Innovative Development of Photoelectric Medical Aesthetics:

May 6, 2023

Venue:

Shanghai Zhangjiang Science Hall (No. 1393 Haike Road, Pudong New Area, Shanghai)

Conference Registration: